Docoh
Loading...

MBRX Moleculin Biotech

Filed: 28 May 21, 4:34pm
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 26, 2021
moleculinlogoresizedclear.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
delaware
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)(Commission File No.)(I.R.S. Employer Identification No.)
 
5300 Memorial Drive, Suite 950, Houston ,TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                    Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per shareMBRXThe NASDAQ Stock Market LLC
 
 

 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On May 26, 2021, the Company held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). As of March 29, 2021, the record date for the Annual Meeting, there were 28,444,425 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 14,602,259 shares, or 51.33%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.
 
Proposal 1. Election of Directors - The Company's stockholders elected Walter V. Klemp, Robert George, Michael Cannon, John Climaco, and Elizabeth Cermak to serve until the next Annual Meeting of Stockholders, or until such person's successor is qualified and elected.
 
Director Name
 
Votes For
 
Votes Withheld
 
Broker Non-Votes
Walter V. Klemp 6,628,165  887,165  7,086,929 
Robert George 6,564,757  950,573  7,086,929 
Michael Cannon 6,605,736  909,594  7,086,929 
John Climaco 6,586,025  929,305  7,086,929 
Elizabeth Cermak 6,691,204  824,126  7,086,929 
 
Proposal 2. Ratify Grant Thornton LLP as Independent Registered Public Accountant - The Company's stockholders ratified the appointment of Grant Thornton, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021, by the following vote: 
 
Votes For
 
Votes Against
 
Abstain
14,245,753 229,105 127,401
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MOLECULIN BIOTECH, INC.
 
Date: May 28, 2021
By: /s/ Jonathan P. Foster
Jonathan P. Foster
Chief Financial Officer